Cancer Genetics and Epigenetics, 2025, Vol.13, No.3, 126-135 http://medscipublisher.com/index.php/cge 134 Liu C., Xu C., Cui C., Zhu J., and Xu R., 2018, Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer, OncoTargets and Therapy, 11: 8605-8621. https://doi.org/10.2147/OTT.S171724 Lo Prinzi F., Cortellini A., Minelli A., Parisi A., Signorelli C., Schietroma F., Basso M., Salvatore L., Muscio L., Lucchetti J., Morelli C., Tonini G., Di Cocco B., Gemma D., Polito M., Vincenzi B., Trombetta G., Zoratto F., Anghelone A., Veroli M., Nitti D., Calegari M., Di Giacomo E., and Angotti L., 2025, Aflibercept-based and bevacizumab-based second line regimens in patients with metastatic colorectal cancer: propensity score weighted-analysis from a multicenter cohort, Clinical Colorectal Cancer, 24(2): 207-217. https://doi.org/10.1016/j.clcc.2024.12.007 Lungulescu C., Luca I., Dinu I., Negulescu M., Croitoru V., Diculescu M., Gramaticu I., Bogdan D., Croitoru A., Alexandrescu S., Turcu-Știolică A., Mihăilă M., Miron M., Dumitrașcu T., Cazacu I., Buică F., and Lungulescu C., 2023, Bevacizumab treatment for metastatic colorectal cancer in real-world clinical practice, Medicina, 59(2): 350. https://doi.org/10.3390/medicina59020350 Luo H., Wang G., Ke L., Xu H., Hu X., Cao L., Wang C., Chen W., Yan Y., Niu J., Wu S., Li H., and He Y., 2025, Bevacizumab plus mFOLFOX6/FOLFIRI sequential bevacizumab plus capecitabine maintenance in RAS-mutated advanced colorectal cancer: a real-world study of first-line/second-line conversion therapy, Journal of Clinical Oncology, 43(4): 77. https://doi.org/10.1200/jco.2025.43.4_suppl.77 Matsumoto T., Yamazaki K., Kawamoto Y., Moriwaki T., Sugimoto N., Kito Y., Shimada Y., Yukami H., Funakoshi T., Takashima A., Sonoda H., Shindo Y., Ishikawa T., Ohori H., Yamamoto Y., Okuyama H., Yamaguchi T., Nagasu S., Hasegawa H., Baba E., Kataoka M., Kondo C., Esaki T., Kagawa Y., Yamaguchi T., and Sato T., 2024, Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study, InternationalJournal of Clinical Oncology, 29(12): 1878-1886. https://doi.org/10.1007/s10147-024-02613-0 Mazier M., Peeters M., Canon J., Berry S., Georgoulias V., Kretzschmar A., Dibartolomeo M., Michael M., Rivera F., Bridgewater J., Cutsem E., and Cunningham D., 2009, Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study, Annals of Oncology, 20(11): 1842-1847. https://doi.org/10.1093/annonc/mdp233 Motl S., 2005, Bevacizumab in combination chemotherapy for colorectal and other cancers, American Journal of Health-System Pharmacy , 62(10): 1021-1032. https://doi.org/10.1093/AJHP/62.10.1021 Muller M., Tournigand C., Guimbaud R., Hautefeuille V., Lobet S., Darrius R., Tougeron D., Laplaige P., Lecomte T., Jary M., Metges J., Artru P., Mineur L., Paintaud G., Bouche O., Foubert F., Borg C., Monmousseau F., Ternant D., Aparicio T., Ducreux M., Bejan-Angoulvant T., Phelip J., Desgrippes R., Bouhier-Leporrier K., Giraudeau B., and Lepage C., 2025, Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: s double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial), Digestive and Liver Disease, 57(5): 624-630. https://doi.org/10.1016/j.dld.2025.02.002 Pavlidis E., and Pavlidis T., 2013, Role of bevacizumab in colorectal cancer growth and its adverse effects: a review, World Journal of Gastroenterology, 19(31): 5051-5060. https://doi.org/10.3748/wjg.v19.i31.5051 Romera A., Bondarenko I., Franke F., Bariani G., Huerga C., Ostwal V., Shparyk Y., Abdalla K., Millán S., Shah P., Rahuman S., Ramesh A., Peredpaya S., Roca E., Del Campo García A., Cruz F., and Paravisini A., 2018, Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial, The Lancet, Gastroenterology and Hepatology, 3(12): 845-855. https://doi.org/10.1016/S2468-1253(18)30269-3 Saini S., and Hurwitz H., 2006, Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events, Seminars in Oncology, 33(5 Suppl 10): S26-S34. https://doi.org/10.1053/J.SEMINONCOL.2006.08.001 Tonini G., Falcone A., Allegrini G., Chiara S., Carlomagno C., Spadi R., Masi G., Zagonel V., Cremolini C., Buonadonna A., Lonardi S., Loupakis F., Boni L., Ronzoni M., Zaniboni A., Salvatore L., Amoroso D., Tomasello G., Boni C., and Cortesi E., 2014, Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer, The New England Journal of Medicine, 371(17): 1609-1618. https://doi.org/10.1056/NEJMoa1403108 Tsuji Y., Taku K., Fujikawa K., Hosokawa A., Murata K., Nagase M., Shinozaki K., Funai S., Tamura F., Tsushima T., Tsuda M., Yamashita H., Taira K., Okabe M., Yoshida M., Boku N., Seki N., Shinozaki E., Sugimoto N., Ueda S., Nakashima K., Ando M., Suzuki K., Muro K., Sato M., Hirashima T., Esaki T., Tamura T., Morita S., Yamazaki K., Hara H., Hyodo I., Nakajima T., Umeki M., Shibata Y., Kurimoto T., Moriwaki T., Kawakami K., Tsuji A., Nishina T., Denda T., Otsuji T., Takayama T., Baba E., Okuno T., Shimura T., Suyama K., and Tamagawa H., 2016, Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G), Annals of Oncology, 27(8): 1539-1546. https://doi.org/10.1093/annonc/mdw206 Verma N., Kazmi S., Jones A., Abunafeesa H., Hsieh D., Brown T., Kainthla R., and Mutar S., 2025, Phase II single-arm, single-center clinical trial of all-trans-retinoic acid, bevacizumab, and atezolizumab in refractory microsatellite stable colorectal cancer, Journal of Clinical Oncology, 43(4_suppl): tps324.
RkJQdWJsaXNoZXIy MjQ4ODYzNA==